Reaction phenotyping of vinblastine metabolism in dogs

Veterinary and Comparative Oncology

Volumn 14, Issue 2, 2016, Pages 161-169

  Achanta, S ^a,b   Maxwell, L K ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A12; Dogs; Metabolism; Microsomes; Phenotyping; Vinblastine

Indexed keywords

ANTIBODY; CYTOCHROME P450; RECOMBINANT PROTEIN; VINBLASTINE;

ANIMAL; DOG; LIVER MICROSOME; METABOLISM;

ANIMALS; ANTIBODIES; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; MICROSOMES, LIVER; RECOMBINANT PROTEINS; VINBLASTINE;

EID: 84893648237     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12084     Document Type: Article

References (38)

1. Chabner BA, Myers CE and Oliverio VT. Clinical pharmacology of anticancer drugs. Seminars in Oncology 1977; 4: 165-191.
2. Creasey WA, Scott AI, Wei CC, Kutcher J, Schwartz A and Marsh JC. Pharmacological studies with vinblastine in the dog. Cancer Research 1975; 35: 1116-1120.
3. Thamm DH, Turek MM and Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Science 2006; 68: 581-587.
4. Gropp FN, Greger DL, Morel C, Sauter S and Blum JW. Nuclear receptor and nuclear receptor target gene messenger ribonucleic acid levels at different sites of the gastrointestinal tract and in liver of healthy dogs. Journal of Animal Science 2006; 84: 2684-2691.
5. Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, Fitzgerald SD, Gamble D, Ginn PE, Goldschmidt MH, Hendrick MJ, Howerth EW, Janovitz EB, Langohr I, Lenz SD, Lipscomb TP, Miller MA, Misdorp W, Moroff S, Mullaney TP, Neyens I, O'Toole D, Ramos-Vara J, Scase TJ, Schulman FY, Sledge D, Smedley RC, Smith K, Snyder PW, Southorn E, Stedman NL, Steficek BA, Stromberg PC, Valli VE, Weisbrode SE, Yager J, Heller J and Miller R. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Veterinary Pathology 2011; 48: 147-155.
6. Rassnick KM, Bailey DB, Flory AB, Balkman CE, Kiselow MA, Intile JL and Autio K. Efficacy of vinblastine for treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008; 22: 1390-1396.
7. Thamm DH, Mauldin EA and Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor - 41 cases (1992-1997). Journal of Veterinary Internal Medicine 1999; 13: 491-497.
8. Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, Kurzman I and Vail DM. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia(R)) in dogs: a phase I dose-finding study. Veterinary and Comparative Oncology 2012; 10: 174-183.
9. Yancey MF, Merritt DA, White JA, Marsh SA and Locuson CW. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs. Journal of Veterinary Pharmacology and Therapeutics 2010; 33: 154-161.
10. Eagling VA, Tjia JF and Back DJ. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology 1998; 45: 107-114.
11. Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K and Court MH. Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences. Xenobiotica 2000; 30: 575-588.
12. Lu AY, Wang RW and Lin JH. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metabolism and Disposition 2003; 31: 345-350.
13. Kuroha M, Kuze Y, Shimoda M and Kokue E. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. American Journal of Veterinary Research 2002; 63: 900-905.
14. Lu P, Singh SB, Carr BA, Fang Y, Xiang CD, Rushmore TH, Rodrigues AD and Shou M. Selective inhibition of dog hepatic CYP2B11 and CYP3A12. Journal of Pharmacology and Experimental Therapeutics 2005; 313: 518-528.
15. Locuson CW, Ethell BT, Voice M, Lee D and Feenstra KL. Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase. Drug Metabolism and Disposition 2009; 37: 457-461.
16. Mills BM, Zaya MJ, Walters RR, Feenstra KL, White JA, Gagne J and Locuson CW. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs. Drug Metabolism and Disposition 2010; 38: 396-404.
17. Eguchi K, Nishibe Y, Baba T and Ohno K. Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay. Xenobiotica 1996; 26: 755-763.
18. Fukunuga K, Fukunaga K, Sahara H and Orito K. Effects of St. John's wort on pharmacokinetics of cyclosporine and cytochrome P450 gene expression in dogs. ACVIM 2010; 24: 776.
19. Nath A and Atkins WM. A theoretical validation of the substrate depletion approach to determining kinetic parameters. Drug Metabolism and Disposition 2006; 34: 1433-1435.
20. Komura H, Kawase A and Iwaki M. Application of substrate depletion assay for early prediction of nonlinear pharmacokinetics in drug discovery: assessment of nonlinearity of metoprolol, timolol, and propranolol. Journal of Pharmaceutical Sciences 2005; 94: 2656-2666.
21. Obach RS. Predicting clearance in humans from in vitro data. Current Topics in Medicinal Chemistry 2011; 11: 334-339.
22. Schneider WC. Intracellular distribution of enzymes; the oxidation of octanoic acid by rat liver fractions. Journal of Biological Chemistry 1948; 176: 259-266.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976; 72: 248-254.
24. Kajbaf M, Longhi R, Montanari D, Vinco F, Rigo M, Fontana S and Read KD. A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry. Drug Metabolism Letters 2011; 5: 30-39.
25. Achanta S, Ngo M, Veitenheimer A, Maxwell LK and Wagner JR. Simultaneous quantification of vinblastine and desacetylvinblastine concentrations in canine plasma and urine samples using LC-APCI-MS/MS. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2013; 913-914: -147-154.
26. Obach RS and Reed-Hagen AE. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metabolism and Disposition 2002; 30: 831-837.
27. Stringer RA, Strain-Damerell C, Nicklin P and Houston JB. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metabolism and Disposition 2009; 37: 1025-1034.
28. Gelboin HV, Krausz KW, Shou M, Gonzalez FJ and Yang TJ. A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics 1997; 7: 469-477.
29. Granvil CP, Krausz KW, Gelboin HV, Idle JR and Gonzalez FJ. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. Journal of Pharmacology and Experimental Therapeutics 2002; 301: 1025-1032.
30. Komura H and Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. Journal of Pharmaceutical Sciences 2008; 97: 1775-1800.
31. Mills BM, Zaya MJ, Walters RR, Feenstra KL, White JA, Gagne J and Locuson CW. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs. Drug Metab Dispos 2010; 38: 396-404.
32. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y and Rahmani R. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Research 1993; 53: 5121-5126.
33. Beulz-Riche D, Grude P, Puozzo C, Sautel F, Filaquier C, Riche C and Ratanasavanh D. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundamental and Clinical Pharmacology 2005; 19: 545-553.
34. Kajita J, Kuwabara T, Kobayashi H and Kobayashi S. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metabolism and Disposition 2000; 28: 1121-1127.
35. Topletz AR, Dennison JB, Barbuch RJ, Hadden CE, Hall SD and Renbarger JL. The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine. Drug Metabolism and Disposition 2013.
36. Bosch TM, Meijerman I, Beijnen JH and Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clinical Pharmacokinetics 2006; 45: 253-285.
37. Kamimura H. Genetic polymorphism of cytochrome P450s in beagles: possible influence of CYP1A2 deficiency on toxicological evaluations. Archives of Toxicology 2006; 80: 732-738.
38. Zhou SF, Liu JP and Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 2009; 41: 89-295.